Browse > Article
http://dx.doi.org/10.3746/jkfn.2013.42.9.1363

Induction of Apoptosis by Combination Treatment with Luteolin and TRAIL in T24 Human Bladder Cancer Cells  

Park, Hyun Soo (School of Korean Medicine, Pusan National University)
Choi, Yung Hyun (Dept. of Biochemistry, College of Oriental Medicine, Dongeui University)
Publication Information
Journal of the Korean Society of Food Science and Nutrition / v.42, no.9, 2013 , pp. 1363-1369 More about this Journal
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis by targeting cancer cells. However, some cancer cells are resistant to TRAIL-induced cytotoxicity. One method of overcoming TRAIL resistance is combination treatment with reagents to sensitize cells to TRAIL. Luteolin, a flavonoid, has been shown to have anti-cancer effects by inducing apoptosis and cell cycle arrest in various cancer cell lines in vitro. In this study, we investigated the effects of combination treatment with non-toxic concentration of TRAIL and luteolin in T24 human bladder cancer cells. Combined treatment with luteolin and TRAIL significantly inhibits cell proliferation via activation of caspases by inducing Bid truncation, up-regulation of Bax and down-regulation of X-linked inhibitor of apoptosis protein (XIAP). However, the apoptotic effects of combination treatment with luteolin and TRAIL were significantly inhibited by specific caspases inhibitors. Taken together, these results indicate that combination treatment with TRAIL and luteolin can induce apoptosis in TRAIL-resistant cancer cells through down-regulation of XIAP and modulation of tBid and Bax expression.
Keywords
T24; luteolin; TRAIL; apoptosis; caspase;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. 2005. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34.   DOI   ScienceOn
2 Nargund VH, Tanabalan CK, Kabir MN. 2012. Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol 39: 559-572.   DOI   ScienceOn
3 Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. 2008. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72: 613-616.   DOI   ScienceOn
4 Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce S, Simone S, Bucci R, Farber E. 2002. Cell death: apoptosis versus necrosis (review). Int J Oncol 21: 165-170.
5 Han SI, Kim YS, Kim TH. 2008. Role of apoptotic and necrotic cell death under physiologic conditions. BMB Rep 41: 1-10.   과학기술학회마을   DOI   ScienceOn
6 Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516.   DOI   ScienceOn
7 Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21: 485-495.   DOI   ScienceOn
8 Riedl SJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.   DOI   ScienceOn
9 Le Marchand L. 2002. Cancer preventive effects of flavonoids-a review. Biomed Pharmacother 56: 296-301.   DOI   ScienceOn
10 Arts IC. 2008. A review of the epidemiological evidence on tea, flavonoids, and lung cancer. J Nutr 138: 1561S-1566S.
11 Romagnolo DF, Selmin OI. 2012. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 31: 206-238.   DOI
12 Seelinger G, Merfort I, Schempp CM. 2008. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 74: 1667-1677.   DOI   ScienceOn
13 Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH. 2005. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 203:124-131.   DOI   ScienceOn
14 Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. 2008. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 87: 401-406.   DOI   ScienceOn
15 Shi RX, Ong CN, Shen HM. 2005. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 65: 7815-7823.   DOI
16 Park SH, Park HS, Lee JH, Chi GY, Kim GY, Moon SK, Chang YC, Hyun JW, Kim WJ, Choi YH. 2013. Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy by luteolin in NCI-H460 lung carcinoma cells. Food Chem Toxicol 56: 100-109.   DOI   ScienceOn
17 Ou YC, Kuan YH, Li JR, Raung SL, Wang CC, Hung YY, Chen CJ. 2012. Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells. J Evidence-Based Complementary Altern Med Vol 2013, Article ID 109105.
18 Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, Chen G, Zhang Z, Luo J, Shi X. 2012. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 7: e52279. doi: 10.1371/journal.pone.0052279.   DOI
19 Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T. 2005. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 333: 833-838.   DOI   ScienceOn
20 Yan J, Wang Q, Zheng X, Sun H, Zhou Y, Li D, Lin Y, Wang X. 2012. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun 417: 842-846.   DOI   ScienceOn
21 Almasan A, Ashkenazi A. 2003. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348.   DOI   ScienceOn
22 Holoch PA, Griffith TS. 2009. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625: 63-72.   DOI   ScienceOn
23 Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237.   DOI   ScienceOn
24 Steinwede K, Henken S, Bohling J, Maus R, Ueberberg B, Brumshagen C, Brincks EL, Griffith TS, Welte T, Maus UA. 2012. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 209: 1937-1952.   DOI
25 Falschlehner C, Emmerich CH, Gerlach B, Walczak H. 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475.   DOI   ScienceOn